miR‑215 promotes epithelial to mesenchymal transition and proliferation by regulating LEFTY2 in endometrial cancer

Gao,Xiaoxu; Cai,Yan; An,Ruifang

doi:10.3892/ijmm.2018.3703

miR‑215 promotes epithelial to mesenchymal transition and proliferation by regulating LEFTY2 in endometrial cancer

Authors:
- Xiaoxu Gao
- Yan Cai
- Ruifang An
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, Shaanxi 710061, P.R. China, Department of Gynecology and Obstetrics, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: May 22, 2018 https://doi.org/10.3892/ijmm.2018.3703
Pages: 1229-1236
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endometrial cancer (EC) is the most common gynecological tumor in developed countries with an increasing incidence. Left‑right determination factor 2 (LEFTY2), a suppressor of cell proliferation and tumor growth, is a negative regulator of EC progression. The roles of LEFTY2 are emerging; however, the regulatory mechanisms of its expression have not been well understood. MicroRNA (miR)‑215 as an oncogene serves an important role in tumorigenesis by regulating target genes. In the present study, it was demonstrated that overexpression of miR‑215 promoted epithelial to mesenchymal transition (EMT), colony formation and DNA synthesis in EC HEC‑1A cells and its expression was upregulated in EC tissues. Using online miR target prediction software, it was revealed that LEFTY2 is predicted as a target of miR‑215. Using western blot analysis and immunofluorescence assays, it was demonstrated that overexpression of miR‑215 markedly downregulated LEFTY2 protein expression levels in HEC‑1A cells and LEFTY2 protein expression was downregulated in EC tissues, which was inversely correlated with miR‑215 expression. Furthermore, the present study indicated that overexpression of LEFTY2 protein promoted mesenchymal to epithelial transition and sensitized HEC‑1A cells to cisplatin treatment. In addition, it was revealed that the overexpression of LEFTY2 inhibited colony formation and DNA synthesis in HEC‑1A cells. Thus, miR‑215 may promote EMT and proliferation by regulating LEFTY2 in EC.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar
2	Organization WH and Kurman RJ: WHO classification of tumours of female reproductive organs. Internat Agency for Research on Cancer. 2014.
3	Nieto MA: The ins and outs of the epithelial to mesenchymal transition in health and disease. Ann Rev Cell Dev Biol. 27:347–376. 2011. View Article : Google Scholar
4	Savagner P, Yamada KM and Thiery JP: The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition. J Cell Biol. 137:1403–1419. 1997. View Article : Google Scholar : PubMed/NCBI
5	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
6	Gravdal K, Halvorsen OJ, Haukaas SA and Akslen LA: A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res. 13:7003–7011. 2007. View Article : Google Scholar : PubMed/NCBI
7	Hader C, Marlier A and Cantley L: Mesenchymal-epithelial transition in epithelial response to injury: The role of Foxc2. Oncogene. 29:1031–1040. 2010. View Article : Google Scholar :
8	Miska EA: How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev. 15:563–568. 2005. View Article : Google Scholar : PubMed/NCBI
9	Jannot G and Simard M: Tumour-related microRNAs functions in Caenorhabditis elegans. Oncogene. 25:6197–6201. 2006. View Article : Google Scholar : PubMed/NCBI
10	Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, Dina RE, Brosens JJ, Ghaem-Maghami S and Lam EW: Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res. 70:367–377. 2010. View Article : Google Scholar
11	Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ, Miller DS and Huang TH: Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res. 69:9038–9046. 2009. View Article : Google Scholar : PubMed/NCBI
12	Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I, Susumu N, Aoki D and Inazawa J: miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res. 71:6450–6462. 2011. View Article : Google Scholar : PubMed/NCBI
13	Vandenboom Ii TG, Li Y, Philip PA and Sarkar FH: MicroRNA and cancer: Tiny molecules with major implications. Curr Genomics. 9:97–109. 2008. View Article : Google Scholar
14	Wei Y, Sun J and Li X: MicroRNA-215 enhances invasion and migration by targeting retinoblastoma tumor suppressor gene 1 in high-grade glioma. Biotechnol Lett. 39:197–205. 2017. View Article : Google Scholar
15	Ohyashiki K, Umezu T, Katagiri S, Kobayashi C, Azuma K, Tauchi T, Okabe S, Fukuoka Y and Ohyashiki JH: Downregulation of Plasma miR-215 in chronic myeloid leukemia patients with successful discontinuation of imatinib. Int J Mol Sci. 17:5702016. View Article : Google Scholar : PubMed/NCBI
16	Li N, Zhang QY, Zou JL, Li ZW, Tian TT, Dong B, Liu XJ, Ge S, Zhu Y, Gao J and Shen L: miR-215 promotes malignant progression of gastric cancer by targeting RUNX1. Oncotarget. 7:4817–4828. 2016.
17	Ulloa L, Creemers JW, Roy S, Liu S, Mason J and Tabibzadeh S: Lefty proteins exhibit unique processing and activate the MAPK pathway. J Biol Chem. 276:21387–21396. 2001. View Article : Google Scholar : PubMed/NCBI
18	Cornet PB, Picquet C, Lemoine P, Osteen KG, Bruner-Tran KL, Tabibzadeh S, Courtoy PJ, Eeckhout Y, Marbaix E and Henriet P: Regulation and Function of LEFTY-A/EBAF in the human endometrium mRNA expression during the menstrual cycle, control by progesterone, and effect on matrix metalloproteinases. J Biol Chem. 277:42496–42504. 2002. View Article : Google Scholar : PubMed/NCBI
19	Ulloa L and Tabibzadeh S: Lefty inhibits receptor-regulated Smad phosphorylation induced by the activated transforming growth factor-beta receptor. J Biol Chem. 276:21397–21404. 2001. View Article : Google Scholar : PubMed/NCBI
20	Salker MS, Christian M, Steel JH, Nautiyal J, Lavery S, Trew G, Webster Z, Al-Sabbagh M, Puchchakayala G, Föller M, et al: Deregulation of the serum- and glucocorticoid-inducible kinase SGK1 in the endometrium causes reproductive failure. Nat Med. 17:1509–1513. 2011. View Article : Google Scholar : PubMed/NCBI
21	Alowayed N, Salker MS, Zeng N, Singh Y and Lang F: LEFTY2 controls migration of human endometrial cancer cells via focal adhesion kinase activity (FAK) and miRNA-200a. Cell Physiol Biochem. 39:815–826. 2016. View Article : Google Scholar : PubMed/NCBI
22	Chen Z, Dai Y, Dong Z, Li M, Mu X, Zhang R, Wang Z, Zhang W, Lang J, Leng J and Jiang X: Co-cultured endometrial stromal cells and peritoneal mesothelial cells for an in vitro model of endometriosis. Integr Biol (Camb). 4:1090–1095. 2012. View Article : Google Scholar
23	Liao XH, Lu DL, Wang N, Liu LY, Wang Y, Li YQ, Yan TB, Sun XG, Hu P and Zhang TC: Estrogen receptor α mediates proliferation of breast cancer MCF-7 cells via a p21/PCNA/E2F1-dependent pathway. FEBS J. 281:927–942. 2014. View Article : Google Scholar
24	Xiang Y, Lu DL, Li JP, Yu CX, Zheng DL, Huang X, Wang ZY, Hu P, Liao XH and Zhang TC: Myocardin inhibits estrogen receptor alpha-mediated proliferation of human breast cancer MCF-7 cells via regulating MicroRNA expression. IUBMB Life. 68:477–487. 2016. View Article : Google Scholar : PubMed/NCBI
25	Liao XH, Wang N, Zhao DW, Zheng DL, Zheng L, Xing WJ, Ma WJ, Bao LY, Dong J and Zhang TC: STAT3 protein regulates vascular smooth muscle cell phenotypic switch by interaction with myocardin. J Biol Chem. 290:19641–19652. 2015. View Article : Google Scholar : PubMed/NCBI
26	Zhang WL and Zhang JH: miR-181c promotes proliferation via suppressing PTEN expression in inflammatory breast cancer. Int J Oncol. 46:2011–2020. 2015. View Article : Google Scholar : PubMed/NCBI
27	Zhang WL, Lv W, Sun SZ, Wu XZ and Zhang JH: miR-206 inhibits metastasis-relevant traits by degrading MRTF-A in anaplastic thyroid cancer. Int J Oncol. 47:133–142. 2015. View Article : Google Scholar : PubMed/NCBI
28	Zhang WL, Zhang JH, Wu XZ, Yan T and Lv W: miR-15b promotes epithelial-mesenchymal transition by inhibiting SMURF2 in pancreatic cancer. Int J Oncol. 47:1043–1053. 2015. View Article : Google Scholar : PubMed/NCBI
29	Liao XH, Wang N, Zhao DW, Zheng DL, Zheng L, Xing WJ, Zhou H, Cao DS and Zhang TC: NF-κB (p65) negatively regulates myocardin-induced cardiomyocyte hypertrophy through multiple mechanisms. Cell Signal. 26:2738–2748. 2014. View Article : Google Scholar : PubMed/NCBI
30	Liao XH, Wang N, Liu LY, Zheng L, Xing WJ, Zhao DW, Sun XG, Hu P, Dong J and Zhang TC: MRTF-A and STAT3 synergistically promote breast cancer cell migration. Cell Signal. 26:2370–2380. 2014. View Article : Google Scholar : PubMed/NCBI
31	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
32	Fu TG, Wang L, Li W, Li JZ and Li J: miR-143 inhibits oncogenic traits by degrading NUAK2 in glioblastoma. Int J Mol Med. 37:1627–1635. 2016. View Article : Google Scholar : PubMed/NCBI
33	Ren ZG, Dong SX, Han P and Qi J: miR-203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer. Oncol Rep. 35:1365–1374. 2016. View Article : Google Scholar : PubMed/NCBI
34	Liao XH, Li YQ, Wang N, Zheng L, Xing WJ, Zhao DW, Yan TB, Wang Y, Liu LY, Sun XG, et al: Re-expression and epigenetic modification of maspin induced apoptosis in MCF-7 cells mediated by myocardin. Cell Signal. 26:1335–1346. 2014. View Article : Google Scholar : PubMed/NCBI
35	Liao XH, Wang Y, Wang N, Yan TB, Xing WJ, Zheng L, Zhao DW, Li YQ, Liu LY, Sun XG, et al: Human chorionic gonadotropin decreases human breast cancer cell proliferation and promotes differentiation. IUBMB Life. 66:352–360. 2014. View Article : Google Scholar : PubMed/NCBI
36	Liao XH, Xiang Y, Yu CX, Li JP, Li H, Nie Q, Hu P, Zhou J and Zhang TC: STAT3 is required for miR-17 5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells. Oncotarget. 8:15763–15774. 2017. View Article : Google Scholar : PubMed/NCBI
37	Liao XH, Li JY, Dong XM, Wang X, Xiang Y, Li H, Yu CX, Li JP, Yuan BY, Zhou J and Zhang TC: ERα inhibited myocardin-induced differentiation in uterine fibroids. Exp Cell Res. 350:73–82. 2017. View Article : Google Scholar
38	Yoshikawa K, Noguchi K, Nakano Y, Yamamura M, Takaoka K, Hashimoto-Tamaoki T and Kishimoto H: The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma. Int J Oncol. 46:2364–2370. 2015. View Article : Google Scholar : PubMed/NCBI
39	Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
40	Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Müller P, et al: Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 408:86–89. 2000. View Article : Google Scholar : PubMed/NCBI
41	Liao XH, Dong X, Wu C, Wang T, Liu F, Zhou J and Zhang TC: Human cytomegalovirus immediate early protein 2 enhances myocardin-mediated survival of rat aortic smooth muscle cells. Virus Res. 192:85–91. 2014. View Article : Google Scholar : PubMed/NCBI
42	Xing WJ, Liao XH, Wang N, Zhao DW, Zheng L, Zheng DL, Dong J and Zhang TC: MRTF-A and STAT3 promote MDA-MB-231 cell migration via hypermethylating BRSM1. IUBMB Life. 67:202–217. 2015. View Article : Google Scholar : PubMed/NCBI
43	He H and Magi-Galluzzi C: Epithelial-to-mesenchymal transition in renal neoplasms. Adv Anat Pathol. 21:174–180. 2014. View Article : Google Scholar : PubMed/NCBI
44	Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601. 2008. View Article : Google Scholar : PubMed/NCBI
45	Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J and Sakuragi N: MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer. 10:992011. View Article : Google Scholar : PubMed/NCBI
46	Klymkowsky MW and Savagner P: Epithelial-mesenchymal transition: A cancer researcher’s conceptual friend and foe. Am J Pathol. 174:1588–1593. 2009. View Article : Google Scholar : PubMed/NCBI
47	Chen J, Wang L, Matyunina LV, Hill CG and McDonald JF: Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol. 121:200–205. 2011. View Article : Google Scholar : PubMed/NCBI
48	Machackova T, Mlcochova H, Stanik M, Dolezel J, Fedorko M, Pacik D, Poprach A, Svoboda M and Slaby O: MiR-429 is linked to metastasis and poor prognosis in renal cell carcinoma by affecting epithelial-mesenchymal transition. Tumour Biol. 37:14653–14658. 2016. View Article : Google Scholar : PubMed/NCBI
49	Sun Y, Shen S, Liu X, Tang H, Wang Z, Yu Z, Li X and Wu M: MiR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma. Mol Cell Biochem. 390:19–30. 2014. View Article : Google Scholar : PubMed/NCBI
50	Wu CL, Ho JY, Chou SC and Yu DS: MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer. Oncotarget. 7:26593–26603. 2016.PubMed/NCBI
51	Qiu M, Liang Z, Chen L, Tan G, Wang K, Liu L, Liu J and Chen H: MicroRNA-429 suppresses cell proliferation, epithelial-mesenchymal transition, and metastasis by direct targeting of BMI1 and E2F3 in renal cell carcinoma. Urol Oncol. 33:332. e9–e82015. View Article : Google Scholar : PubMed/NCBI
52	Deng Y, Huang Z, Xu Y, Jin J, Zhuo W, Zhang C, Zhang X, Shen M, Yan X, Wang L, et al: MiR-215 modulates gastric cancer cell proliferation by targeting RB1. Cancer Lett. 342:27–35. 2014. View Article : Google Scholar
53	Xu YJ and Fan Y: MiR-215/192 participates in gastric cancer progression. Clin Transl Oncol. 17:34–40. 2015. View Article : Google Scholar
54	Scudiero DA: Decreased DNA repair synthesis and defective colony-forming ability of ataxia telangiectasia fibroblast cell strains treated with N-methyl-N’-nitro-N-nitrosoguanidine. Cancer Res. 40:984–990. 1980.PubMed/NCBI
55	Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J and García De Herreros A: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2:84–89. 2000. View Article : Google Scholar : PubMed/NCBI
56	Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al: Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 527:472–476. 2015. View Article : Google Scholar : PubMed/NCBI